AndreaBozzo/ceres-open-data-index huggingface dataset:
Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials

Background
          Hormone replacement therapy (HRT) is often seen as the treatment of choice for preventing fractures in women. We undertook a recent meta-analysis of randomised trials which suggested that HRT reduced non-vertebral fractures by 30%. In this analysis we extend that analysis to vertebral fractures.
        
        
          Methods
          We searched the main electronic databases until the end of August 2001. We sought all randomised controlled trials (RCTs) of HRT where women had been randomised to at least 12 months of HRT or to no HRT.
        
        
          Results
          We found 13 RCTs. Overall there was a 33% reduction in vertebral factures (95% confidence interval (CI) 45% to 98%).
        
        
          Conclusions
          This review and meta-analysis showed a significant reduction in vertebral fractures associated with HRT use.
Antenatal infection/inflammation and postnatal lung maturation and injury

Chorioamnionitis is frequently associated with preterm deliveries before 30 weeks gestation. Chorioamnionitis correlates both with an increased risk of bronchopulmonary dysplasia and with a decreased risk of respiratory distress syndrome. Both interleukin-1α and endotoxin can induce inflammation in the fetal lungs and lung maturation after preterm birth when given by intra-amniotic injection. Inflammation can also result in an arrest of alveolarization, and this lung developmental abnormality is prominent in the lungs of preterm infants that die of bronchopulmonary dysplasia. The mechanisms by which infection/inflammation can have both beneficial and injurious effects on the preterm lung remain to be characterized.
5.2c Clients in treatment, according to type of care received, by facility operation and primary focus of facility: March 31, 2011. Percent distribution (column percent)

This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing clients in treatment, according to type of care received, by facility operation and primary focus of facility in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.
Public Health Statistics - Chlamydia cases among males aged 15-44 in Chicago, by year, 2000-2014 - Historical

Note: This dataset is historical only and STI surveillance data do not change once finalized. For the most recent STI data, please refer to the CDPH Health Atlas (chicagohealthatlas.org), the annual HIV/STI surveillance report, and the Getting to Zero Illinois HIV Dashboard (gtzillinois.hiv).

The annual number of newly reported, laboratory-confirmed cases of chlamydia (Chlamydia trachomatis) among males aged 15-44 years and annual chlamydia incidence rate (cases per 100,000 males aged 15-44 years) with corresponding 95% confidence intervals by Chicago community area, for years 2000 – 2014. See the full description by clicking on the maroon "About" button on the right-hand side of the screen, and click on the PDF under "Attachments".
Effect of paper quality on the response rate to a postal survey: A randomised controlled trial. [ISRCTN32032031]

Background
          Response rates to surveys are declining and this threatens the validity and generalisability of their findings. We wanted to determine whether paper quality influences the response rate to postal surveys
        
        
          Methods
          A postal questionnaire was sent to all members of the British Society of Gynaecological Endoscopy (BSGE). Recipients were randomised to receiving the questionnaire printed on standard quality paper or high quality paper.
        
        
          Results
          The response rate for the recipients of high quality paper was 43/195 (22%) and 57/194 (29%) for standard quality paper (relative rate of response 0.75, 95% CI 0.33–1.05, p = 0.1
        
        
          Conclusion
          The use of high quality paper did not increase response rates to a questionnaire survey of gynaecologists affiliated to an endoscopic society.
Compound 528782: Cyclononacosasiloxane, octapentacontamethyl

Chemical compound data from PubChem database. IUPAC Name: 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16,18,18,20,20,22,22,24,24,26,26,28,28,30,30,32,32,34,34,36,36,38,38,40,40,42,42,44,44,46,46,48,48,50,50,52,52,54,54,56,56,58,58-octapentacontamethyl-1,3,5,7,9,11,13,15,17,19,21,23,25,27,29,31,33,35,37,39,41,43,45,47,49,51,53,55,57-nonacosaoxa-2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,50,52,54,56,58-nonacosasilacyclooctapentacontane. Molecular Formula: C58H174O29Si29. Molecular Weight: 2150.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Research Article: BMC Pharmacology

Background
          Leishmaniasis is a common parasitic disease in Southern Europe, caused by Leishmania infantum. The failures of current treatment with pentavalent antimonials are partially attributable to the emergence of antimony-resistant Leishmania strains. This study analyses the in vitro susceptibility to pentavalent antimony of intracellular amastigotes from a range of L. infantum strains, derived from the same infected animal, during in vitro and in vivo passages and after host treatment with meglumine antimoniate.
        
        
          Results
          SbV-IC50 values for strains from two distinct isolates from the same host and one stock after two years of culture in NNN medium and posterior passage to hamster were similar (5.0 ± 0.2; 4.9 ± 0.2 and 4.4 ± 0.1 mgSbV/L, respectively). In contrast, a significant difference (P < 0.01, t test) was observed between the mean SbV-IC50 values in the stocks obtained before and after treatment of hosts with meglumine antimoniate (4.7 ± 0.4 mgSbV/L vs. 7.7 ± 1.5 mgSbV/L). Drug-resistance after drug pressure in experimentally infected dogs increased over repeated drug administration (6.4 ± 0.5 mgSbV/L after first treatment vs. 8.6 ± 1.4 mgSbV/L after the second) (P < 0.01, t test).
        
        
          Conclusions
          These results confirm previous observations on strains from Leishmania/HIV co-infected patients and indicate the effect of the increasing use of antimony derivatives for treatment of canine leishmaniasis in endemic areas on the emergence of Leishmania antimony-resistant strains.
Patent AT-E401002-T1: [Translated] ANNOLATED HETEROCYCLIC SULFONYL UREA COMPOUND, HERBICIDE CONTAINING SAME AND METHOD FOR CONTROLLING WEEDS USING THIS COMPOUND

The present invention provides a compound represented by the formula: <CHEM> wherein Q represents a fused heterocyclic group, X and Y are the same or different and each represent an optionally halogenated lower alkyl group, an optionally halogenated lower alkoxy group, etc. , or a salt thereof, as well as a herbicide comprising the compound or a salt thereof, which exhibits a significant effect for control of sulfonylurea herbicide-resistant weeds in paddy fields and can reduce the number of active ingredients in a combined preparation and a method of controlling sulfonylurea herbicide-resistant weeds which comprises using the same.
Compound 528929: Benzaldehyde, 2-hydroxy, 5-dodecyl, oxime, TMS

Chemical compound data from PubChem database. IUPAC Name: 1-(5-dodecyl-2-trimethylsilyloxyphenyl)-N-trimethylsilyloxymethanimine. Molecular Formula: C25H47NO2Si2. Molecular Weight: 449.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399761-T1: [Translated] METHOD FOR PRODUCING DINITRILES

Chemical patent from PubChem database. Patent Number: AT-E399761-T1. Title: Pharmaceutical Formulation and Method of Use. Filing Date: 2012-02-02. Inventors: Martinez, Carlos, Thompson, Emily. Abstract: The invention relates to pharmaceutical formulations containing active ingredients and methods for their therapeutic use in treating various medical c... IPC Classifications: B01J, C07C, C07D. This patent covers 17 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 526886: Tetraethylene glycol, pentyl ether, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[2-[2-[2-(2-pentoxyethoxy)ethoxy]ethoxy]ethoxy]silane. Molecular Formula: C16H36O5Si. Molecular Weight: 336.54. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
State Snapshots

<p>The State Snapshots provide graphical representations of State-specific health care quality information, including strengths, weaknesses, and opportunities for improvement. The goal is to help State officials and their public- and private-sector partners better understand health care quality and disparities in their State. State-level information used to create the State Snapshots is based on data collected for the National Healthcare Quality Report (NHQR). The State Snapshots include summary measures of quality of care and States' performances relative to all States, the region, and best performing States by overall health care quality, types of care (preventive, acute, and chronic), settings of care (hospitals, ambulatory care, nursing home, and home health), and clinical conditions (cancer, diabetes, heart disease, maternal and child health, and respiratory diseases). Special focus areas on diabetes, asthma, Healthy People 2010, clinical preventive services, disparities, payer, and variation over time are also featured. The Agency for Healthcare Research and Quality (AHRQ) has released the State Snapshots each year in conjunction with the 2004 NHQR through the 2009 NHQR.</p>
National Directory of Mental Health Treatment Facilities 2012

The National Directory of Mental Health Treatment Facilities for 2012 lists federal facilities (U.S. Department of Veterans Affairs medical centers), state and local government (public) facilities, and private (for profit and nonprofit) facilities that responded to the 2010 National Mental Health Services Survey (N-MHSS), a national survey the Substance Abuse and Mental Health Services Administration (SAMHSA) conducts biennially. The facilities were eligible if they indicated a primary focus of providing mental health treatment services. The information about each facility that appears in this directory was provided by that facility in response to the 2010 N-MHSS. The directory is ordered alphabetically by state, by city within each state, and by facility name within each city.
Compound 530241: 3,7-Dimethyloct-3-ene

Chemical compound data from PubChem database. IUPAC Name: 3,7-dimethyloct-3-ene. Molecular Formula: C10H20. Molecular Weight: 140.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530235: Pentadecane, 6-butyl-7-methyl

Chemical compound data from PubChem database. IUPAC Name: 6-butyl-7-methylpentadecane. Molecular Formula: C20H42. Molecular Weight: 282.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529004: Benzene, 1,2,3-trimethyl-4-(2-propenyl)

Chemical compound data from PubChem database. IUPAC Name: 1,2,3-trimethyl-4-prop-2-enylbenzene. Molecular Formula: C12H16. Molecular Weight: 160.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Mini-laparoscopic versus laparoscopic approach to appendectomy

Background
          The purpose of this clinical study is to evaluate the feasibility of using 2-mm laparoscopic instruments to perform an appendectomy in patients with clinically suspected acute appendicitis and compare the outcome of this mini-laparoscopic or "needlescopic" approach to the conventional laparoscopic appendectomy.
        
        
          Methods
          Two groups of patients undergoing appendectomy over 24 months were studied. In the first group, needlescopic appendectomy was performed in 15 patients by surgeons specializing in advanced laparoscopy. These patients were compared with the second or control group that included 21 consecutive patients who underwent laparoscopic appendectomy. We compared the patients' demographic data, operative findings, complications, postoperative pain medicine requirements, length of hospital stay, and recovery variables. Differences were considered statistically significant at a p-value < 0.05.
        
        
          Results
          Patient demographics, history of previous abdominal surgery, and operative findings were similar in both groups. There was no conversion to open appendectomy in either group. No postoperative morbidity or mortality occurred in either group. The needlescopic group had a significantly shorter mean operative time (p = 0.02), reduced postoperative narcotics requirements (p = 0.05), shorter hospital stay (p = 0.04), and quicker return to work (p = 0.03) when compared with the laparoscopic group.
        
        
          Conclusions
          We conclude that the needlescopic technique is a safe and effective approach to appendectomy. When performed by experienced laparoscopic surgeons, the needlescopic technique results in significantly shorter postoperative convalescence and a prompt recovery.
Behavioral Risk Factor Surveillance Survey: 2010

The Behavioral Risk Factor Surveillance System (BRFSS) is an annual statewide telephone surveillance system designed by the Centers for Disease Control and Prevention (CDC). BRFSS monitors modifiable risk behaviors and other factors contributing to the leading causes of morbidity and mortality in the population. New York State's BRFSS sample represents the non-institutionalized adult household population, aged 18 years and older. 

Although the overall number of respondents in the BRFSS is more than sufficiently large for statistical inference purposes, subgroup analyses can lead to estimates that are unreliable. Interpreting and reporting weighted numbers that are based on a small, unweighted number of respondents can mislead the reader into believing that a given finding is much more precise than it actually is. The BRFSS follows a rule of not reporting or interpreting percentages based upon a denominator of fewer than 50 respondents (unweighted sample). Both a csv and sas data files are available.

For more information, check out http://www.health.ny.gov/statistics/brfss/.
Patent AT-E400611-T1: [Translated] COMPOSITION COEXTRUDABLE WITH PVDF

Chemical patent from PubChem database. Patent Number: AT-E400611-T1. Title: Sustained Release Formulation. Filing Date: 2004-08-11. Inventors: Rodriguez, Juan, White, Jennifer. Abstract: A sustained release formulation is provided, designed to maintain therapeutic drug levels over extended periods, reducing dosing frequency and improvi... IPC Classifications: C08G, C08K, A61K. This patent covers 15 claims related to 9 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Publications Using SAMHSA DataBehavioral Health Equity Barometer

The Behavioral Health Equity Barometer, United States, 2014 provides a snapshot of substance use and mental health indicators by selected determinants of health: race and ethnicity, income level, geographic location, and health insurance status in the United States as measured through the National Survey on Drug Use and Health (NSDUH) data collection efforts sponsored by SAMHSA. The topics addressed in this report include youth substance use, youth mental health and treatment, adult mental health and treatment, substance abuse and substance abuse treatment for the years 2009 to 2013.
North Carolina (NC)

This report presents North Carolina\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for North Carolina for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 525617: N,N-Dimethyl-N'-butyl-p-methylbenzamidine

Chemical compound data from PubChem database. IUPAC Name: N'-butyl-N,N,4-trimethylbenzenecarboximidamide. Molecular Formula: C14H22N2. Molecular Weight: 218.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - Table II. Invasive Pneumococcal to Legionellosis

NNDSS - Table II. Invasive Pneumococcal to Legionellosis - 2016.  In this Table, provisional* cases of selected† notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories.

Note:
These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. 

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. 

Footnotes:
C.N.M.I.: Commonwealth of Northern Mariana Islands. 
U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable.  NP:  Nationally notifiable but not published.    Cum: Cumulative year-to-date counts.    Med: Median.    Max: Maximum.

* Case counts for reporting year 2016 are provisional and subject to change.   For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. 
† Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. 
§ Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
West Virginia 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Compound 526697: 3-O-acetyl-1,5-anhydro-2,4-di-O-methyl-D-fucitol

Chemical compound data from PubChem database. IUPAC Name: (3,5-dimethoxy-2-methyloxan-4-yl) acetate. Molecular Formula: C10H18O5. Molecular Weight: 218.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525880: N,N-Dimethyl-N'-(3-nitrophenyl)-isobutyramidine

Chemical compound data from PubChem database. IUPAC Name: N,N,2-trimethyl-N'-(3-nitrophenyl)propanimidamide. Molecular Formula: C12H17N3O2. Molecular Weight: 235.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Lack of agreement between bioimpedance and continuous thermodilution measurement of cardiac output in intensive care unit patients

Background:
          Bolus thermodilution is the standard bedside method of cardiac output measurement in the intensive care unit (ICU). The Baxter Vigilance monitor uses a modified thermodilution pulmonary artery catheter with a thermal filament to give a continuous read-out of cardiac output. This has been shown to correlate very well with both the 'gold standard' dye dilution method and the bolus thermodilution method. Bioimpedance cardiography using the Bomed NCCOM 3 offers a noninvasive means of continuous cardiac output measurement and has been shown to correlate with the bolus thermodilution method. We investigated the agreement between the continuous bioimpedance and continuous thermodilution methods, enabling acquisition of a large number of simultaneous measurements.
        
        
          Results:
          A total of 2390 paired data points from seven patients were collected. There was no correlation (r2 = 0.01) between the methods. The precision (1.16 l/min/m2) of agreement between the Vigilance and the Bomed, assessed by the Bland-Altam method, was very poor although the bias (-0.16 l/min/m2) appeared fair.
        
        
          Conclusions:
          The Bomed NCCOM 3 bioimpedance monitor shows poor agreement with the Baxter Vigilance continuous thermodilution monitor in a group of general ICU patients and cannot be recommended for cardiac output monitoring in this situation.
2021-2022 NSDUH National Maps of Prevalence Estimates, by State

View national maps covering 35 measures of substance use and mental health by age group and state. The maps are based on the 2021-2022 National Surveys on Drug Use and Health (NSDUH). They use small area estimation (SAE) methods in which state-level NSDUH data are combined with other data from smaller geographies. The combined data are used to create modeled estimates of the civilian, noninstitutionalized population ages 12 and older for each state.The map images are available as a PDF or HTM file.